Glomerulopatia por IgA com crescentes fibrocelulares e associada à psoríase: nefropatia psoriásica?

Rafael Naufel de Sá Rebelo; Rafael Yuri Sano; Nathália Figueiredo de Oliveira; Maria Almerinda Vieira Fernandes Ribeiro  Alves; Sérgio Ricardo Rocha de Araújo; Ronaldo D'Ávila

doi:10.23925/1984-4840.2021v23i3/4a9

Autores

Rafael Naufel de Sá Rebelo Pontifícia Universidade Católica de São Paulo. Faculdade de Ciências Médicas e da Saúde – Sorocaba (SP), Brasil. https://orcid.org/0000-0002-3123-3654
Rafael Yuri Sano Conjunto Hospitalar de Sorocaba – Sorocaba (SP), Brasil.
Nathália Figueiredo de Oliveira Conjunto Hospitalar de Sorocaba – Sorocaba (SP), Brasil.
Maria Almerinda Vieira Fernandes Ribeiro Alves Universidade Estadual de Campinas. Faculdade de Ciências Médicas – Campinas (SP), Brasil.
Sérgio Ricardo Rocha de Araújo Conjunto Hospitalar de Sorocaba – Sorocaba (SP), Brasil.
Ronaldo D'Ávila Pontifícia Universidade Católica de São Paulo. Faculdade de Ciências Médicas e da Saúde – Sorocaba (SP), Brasil.

DOI:

https://doi.org/10.23925/1984-4840.2021v23i3/4a9

Palavras-chave:

glomerulonefrite por IgA, psoríase, artrite psoriásica, adalimumab, inibidores do fator de necrose tumoral

Resumo

Alguns estudos têm demonstrado uma ligação entre glomerulonefrite por IgA e psoríase e/ou uso de drogas anti-TNF. Descrevemos o caso de um paciente com artrite psoriática, em uso de anti-TNF por quatro anos, que apresentou nefropatia por IgA agravada por crescentes na biópsia renal e insuficiência renal necessitando de hemodiálise. Após a realização de terapia com metilprednisolona IV e três meses de corticoide oral, houve melhora significativa na função renal e proteinúria. O tratamento de diálise foi interrompido e tratamentos com SGLT-2 inibidores foram iniciados.

Downloads

Não há dados estatísticos.

Metrics

Carregando Métricas ...

Referências

Lai KN, Leung JCK, Tang SCW. Recent advances in the understanding and management of IgA nephropathy. F1000Res. 2016;5:F1000 Faculty Rev-161. doi: 10.12688/f1000research.7352.1. eCollection 2016.

Floege J, Rauen T, Tang SCW. Current treatment of IgA nephropathy. Semin Immunopathol. 2021;43(5):717-28. doi: 10.1007/s00281-021-00888-3.

Novak J, Barratt J, Julian BA, Renfrow MB. Aberrant gycosylation of the IgA1 molecule in IgA nephropathy. Semin Nephrol. 2018;38(5):461-476. doi: 10.1016/j.semnephrol.2018.05.016.

Wyatt RJ, Julian BA. IgA Nephropathy. N Engl J Med. 2013;368(25):2402-14. doi: 10.1056/NEJMra1206793.

Lv J, Yang Y, Zhang H, Chen W, Pan X, Guo Z, et al. Prediction of outcomes in crescentic IgA nephropathy in a multicenter cohort study. J Am Soc Nephrol. 2013;24(12):2118-25. doi: 10.1681/ASN.2012101017.

Garces CC, Hernandez Garcilazo N, Sharma A, Nader G. Severe psoriasis presenting with rapidly progressive (crescentic) IgA-predominant glomerulonephritis. BMJ Case Rep. 2021;14(5):e242627. doi: 10.1136/bcr-2021-242627.

Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, et al. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1-S276. doi: 10.1016/j.kint.2021.05.021.

Barbour SJ, Coppo R, Zhang H, Liu Z-H, Suzuki Y, Matsuzaki K, et al. Evaluating a new international risk-prediction tool in IgA nephropathy. JAMA Intern Med. 2019;179(7):942-952. doi: 10.1001/jamainternmed.2019.0600.

Saha MK, Julian BA, Novak J, Rizk DV. Secondary IgA nephropathy. Kidney Int. 2018;94(4):674-681. doi: 10.1016/j.kint.2018.02.030. Epub 2018 May 24.

Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496-509. doi: 10.1056/NEJMra0804595.

Kamiya K, Kishimoto M, Sugai J, Komine M, Ohtsuki M. Risk factors for the development of psoriasis. Int J Mol Sci. 2019;20(18):4347. doi: 10.3390/ijms20184347.

Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475. doi: 10.3390/ijms20061475.

Boehncke W-H, Schön MP. Psoriasis. Lancet. 2015;386(9997):983-94. doi: 10.1016/S0140-6736(14)61909-7.

Guilhou J-J, Clot J, Meynadier J, Lapinski H. Immunological aspects of psoriasis. J Invest Dermatol. 1982;78(4):313-5. doi: 10.1111/1523-1747.ep12507392.

Ahuja TS, Funtanilla M, de Groot JJ, Velasco A, Badalamenti J, Wilson S. IgA nephropathy in psoriasis. Am J Nephrol. 1998;18(5):425-9. doi: 10.1159/000013388.

Grandinetti V, Baraldi O, Comai G, Corradetti V, Aiello V, Bini C, et al. Renal dysfunction in psoriatic patients. G Ital Nefrol. 2020;37(1):2020-vol1.

Dervisoglu E, Akturk AS, Yildiz K, Kiran R, Yilmaz A. The spectrum of renal abnormalities in patients with psoriasis. Int Urol Nephrol. 2012;44(2):509-14. doi: 10.1007/s11255-011-9966-1. Epub 2011 Apr 20.

Bounia CA, Theodoropoulou EN, Liossis S-NC. Glomerulonephritis in two patients with SpA treated with TNF-α blockers and a review of the literature. Biologics. 2021;15:61-6. doi: 10.2147/BTT.S297712. eCollection 2021.

Stokes MB, Foster K, Markowitz GS, Ebrahimi F, Hines W, Kaufman D, et al. Development of glomerulonephritis during anti-TNF-α therapy for rheumatoid arthritis. Nephrol Dial Transplant. 2005;20(7):1400-6. doi: 10.1093/ndt/gfh832. Epub 2005 Apr 19.

Krug B, Gonçalves C, Neves C, Barone C, Oliveira Junior H, Leite L. Protocolo Clínico e Diretrizes Terapêuticas da Psoríase. Brasília (DF): Ministério da Saúde; 2020. 79 p.

Hugh JM, Weinberg JM. Update on the pathophysiology of psoriasis. Cutis. 2018;102(5S):6-12.

Dattilo G, Borgia F, Guarneri C, Casale M, Bitto R, Morabito C, et al. Cardiovascular risk in psoriasis: current state of the art. Curr Vasc Pharmacol. 2019;17(1):85-91. doi: 10.2174/1570161115666171116163816.

Manolis AA, Manolis TA, Melita H, Manolis AS. Psoriasis and cardiovascular disease: the elusive link. Int Rev Immunol. 2019;38(1):33-54. doi: 10.1080/08830185.2018.1539084. Epub 2018 Nov 20.

Grewal SK, Wan J, Denburg MR, Shin DB, Takeshita J, Gelfand JM. The risk of IgA nephropathy and glomerular disease in patients with psoriasis: a population-based cohort study. Br J Dermatol. 2017;176(5):1366-1369. doi: 10.1111/bjd.14961. Epub 2017 Mar 5.

Ungprasert P, Raksasuk S. Psoriasis and risk of incident chronic kidney disease and end-stage renal disease: a systematic review and meta-analysis. Int Urol Nephrol. 2018;50(7):1277-1283. doi: 10.1007/s11255-018-1868-z. Epub 2018 Apr 11.

Visconti L, Leonardi G, Buemi M, Santoro D, Cernaro V, Ricciardi CA, et al. Kidney disease and psoriasis: novel evidences beyond old concepts. Clin Rheumatol. 2016;35(2):297-302. doi: 10.1007/s10067-015-3126-4. Epub 2015 Nov 28.

Conti A, Giovannini L, Mandel VD, Odorici G, Lasagni C, Bigi L, et al. Chronic kidney disease in psoriasis: a cohort study. J Dtsch Dermatol Ges. 2020;18(5):438-445. doi: 10.1111/ddg.14087. Epub 2020 Apr 20.

Cecchi R, Seghieri G, Gironi A, Tuci F, Giomi A. Relation between urinary albumin excretion and skin involvement in patients with psoriasis. Dermatology. 1992;185(2):93-5. doi: 10.1159/000247420.

Masson W, Lobo M, Molinero G. Psoriasis and cardiovascular risk: a comprehensive review. Adv Ther. 2020;37(5):2017-33. doi: 10.1007/s12325-020-01346-6. Epub 2020 Apr 20.

Boehncke W-H. Systemic inflammation and cardiovascular comorbidity in psoriasis patients: causes and consequences. Front Immunol. 2018;9:579. doi: 10.3389/fimmu.2018.00579. eCollection 2018.

Vaz AS, Penteado R, Cordinhã C, Carmo C, Gomes C. IgA vasculitis (Henoch-Schönlein purpura) nephritis and psoriasis in a child: is there a relationship? J Bras Nefrol. 2021;43(4):603-607. doi: 10.1590/2175-8239-JBN-2020-0101.

Bantis C, Stangou M, Schlaugat C, Alexopoulos E, Pantzaki A, Memmos D, et al. Is Presence of ANCA in crescentic IgA nephropathy a coincidence or novel clinical entity? A case series. Am J Kidney Dis. 2010;55(2):259-68. doi: 10.1053/j.ajkd.2009.09.031. Epub 2009 Dec 30.

Bhagat Singh AK, Jeyaruban AS, Wilson GJ, Ranganathan D. Adalimumab-induced IgA nephropathy. BMJ Case Rep. 2019;12(3):e226442. doi: 10.1136/bcr-2018-226442.

Wei SS, Sinniah R. Adalimumab therapy exacerbates IgA glomerulonephritis acute renal injury and induces lupus autoantibodies in a psoriasis patient. Case Rep Nephrol. 2013;2013:812781. doi: 10.1155/2013/812781. Epub 2013 Jul 24.

Mertelj T, Smrekar N, Kojc N, Lindič J, Kovač D. IgA Nephropathy in a patient treated with adalimumab. Case Rep Nephrol Dial. 2021;11(2):233-240. doi: 10.1159/000515585. eCollection 2021 May-Aug.